RecruitingNCT02432625
Connective Tissue
Osteogenesis Imperfecta
Also known as brittle bone disease, OI, lobstein syndrome
Osteogenesis imperfecta is a heritable connective tissue disorder caused by defects in type I collagen synthesis, leading to abnormally fragile bones that fracture with minimal or no trauma. Clinical severity ranges from mild forms with rel
ORPHA:666 ↗Gene COL1A1Gene COL1A2Prevalence 1 in 10,000–20,000Onset Congenital or early childhoodGenetic — autosomal dominant (most), autosomal recessive (rare types)
12
studies recruiting now
as of 7 Sept 2026
93
studies registered in total
as of 7 Sept 2026
11
countries with a recruiting site
as of 7 Sept 2026
29 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07062588
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
RecruitingPhase 3NCT07366086
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
RecruitingPhase 2NCT07557446
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
RecruitingNot applicableNCT05927389
Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 12 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Osteogenesis Imperfecta study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: OIF Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Osteogenesis Imperfecta
Osteogenesis imperfecta is a heritable connective tissue disorder caused by defects in type I collagen synthesis, leading to abnormally fragile bones that fracture with minimal or no trauma. Clinical severity ranges from mild forms with relatively few fractures to lethal perinatal forms with extreme skeletal fragility and pulmonary insufficiency. All types share deficient or structurally abnormal collagen as the underlying molecular defect.
Common clinical features
Recurrent low-trauma or spontaneous bone fracturesBlue or grey scleraeShort stature and skeletal deformityDentinogenesis imperfecta (brittle, discoloured teeth)Progressive sensorineural or conductive hearing lossJoint hypermobility and ligamentous laxityKyphoscoliosis
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Teriparatide (Bonsity)
Phase 3Denosumab (Jubbonti)
Phase 3Risedronate Sodium (Actonel)
Phase 3Setrusumab
Phase 3Pamidronate Disodium (Aredia)
Phase 3Somatropin (Genotropin)
Phase 3Zoledronic Acid (Aclasta)
Phase 1Busulfan (Busilvex)
Phase 1Romosozumab (Evenity)
+ 4 more in development
Before you apply
Things trial teams commonly ask about for Osteogenesis Imperfecta. Not eligibility rules; those are set by each study.
- Document fracture history and DEXA bone mineral density results before enrolling — most trials require baseline densitometry and a minimum fracture count in the prior 12 months.
- Bisphosphonate use is a common exclusion criterion; confirm washout periods and current medication regimen with the trial coordinator.
- Type classification (I–V or molecular subtype) is often required; ensure genetic confirmation of COL1A1/COL1A2 pathogenic variant is on file.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).